Currently, there are several studies regarding the use of a pan-cdk inhibitor, flavopiridol, that both inhibits cdk activity and transcriptionally down-modulates cyclin D1 which may effectively inhibit rhabdoid tumor growth. Here, CCND1 is linked to rhabdoid tumor.